Showing results (201-210 of 267) with videos related to

Sort By:
Pageof 27
Cancer Chemotherapy and Pharmacology|August 2, 2011
Phase I study of the synthetic triterpenoid, 2-cyano-3, 12-dioxoolean-1, 9-dien-28-oic acid (CDDO), in advanced solid tumorsGiovanna Speranza, Martin E Gutierrez, Shivaani Kummar, et al.
Future Oncology (London, England)|January 16, 2025
Open-label, phase Ia study of STING agonist BI 1703880 plus ezabenlimab for patients with advanced solid tumorsKevin Harrington, Shigehisa Kitano, Valentina Gambardella, et al.
Frontiers in Medicine|September 28, 2020
Pulmonary Thrombosis or Embolism in a Large Cohort of Hospitalized Patients With Covid-19Natividad Benito, David Filella, Jose Mateo, et al.
ACS Synthetic Biology|September 21, 2016
Rapid and Inexpensive Evaluation of Nonstandard Amino Acid Incorporation in Escherichia coliJordan W Monk, Sean P Leonard, Colin W Brown, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|May 4, 2016
Omission of Breast Radiotherapy in Low-risk Luminal A Breast Cancer: Impact on Health Care CostsK Han, M L Yap, J H E Yong, et al.
Clinical Lung Cancer|January 3, 2025
Phase II Parallel Arm Study of Sacituzumab Govitecan-Hziy in Patients With Advanced Thymoma or Thymic CarcinomaJennifer A Marks, Jaeil Ahn, Joshua E Reuss, et al.
Current Eye Research|March 25, 2014
Choroidal blood flow decreases with age: an MRI studyOscar San Emeterio Nateras, Joseph M Harrison, Eric R Muir, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 20, 2017
Phase I Study of Fenretinide Delivered Intravenously in Patients with Relapsed or Refractory Hematologic Malignancies: A California Cancer Consortium TrialAnn M Mohrbacher, Allen S Yang, Susan Groshen, et al.
The Oncologist|July 9, 2025
First-in-human phase I open-label study of the anti-TIM-3 monoclonal antibody INCAGN02390 in patients with select advanced or metastatic solid tumorsMartin E Gutierrez, Shou-Ching Tang, John D Powderly, et al.
ESMO Open|May 8, 2026
First-in-human study of the dual A<sub>2</sub><sub>A</sub>/A<sub>2</sub><sub>B</sub> adenosine receptor antagonist muvadenant (M1069) in patients with advanced solid tumorsL L Siu, M E Gutierrez, L Pudelko, et al.
Pageof 27